RayKnowChina Research Map
Shortlist0

BeijingCapital Medical University

Beijing Tongren Hospital

首都医科大学附属北京同仁医院

Listed for 25 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Beijing Tongren Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌6 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌1 paper led
  3. Hepatocellular carcinoma肝细胞癌30 papers led
  4. Stomach cancer胃癌15 papers led
  5. Hepatoblastoma肝母细胞瘤8 papers led
  6. Retinoblastoma视网膜母细胞瘤21 papers led
  7. Osteosarcoma骨肉瘤7 papers led
  8. Neuroblastoma神经母细胞瘤9 papers led
  9. Ewing sarcoma尤文肉瘤1 paper led
  10. Multiple myeloma多发性骨髓瘤6 papers led
  11. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led1 open trial led
  12. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症1 paper led1 open trial led
  13. Haemophilia A血友病 A0 papers led
  14. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病7 papers led
  15. IgG4-related diseaseIgG4相关性疾病3 papers led
  16. Myasthenia gravis重症肌无力6 papers led
  17. Wilson disease肝豆状核变性(Wilson 病)3 papers led
  18. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎4 papers led2 open trials led
  19. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  20. Behçet disease白塞病1 paper led
  21. IgA nephropathyIgA 肾病2 papers led
  22. Primary biliary cholangitis原发性胆汁性胆管炎2 papers led
  23. Hirschsprung disease先天性巨结肠1 paper led
  24. Hereditary angioedema遗传性血管性水肿0 papers led
  25. Leber hereditary optic neuropathyLeber 遗传性视神经病变4 papers led

Not listed for: Chordoma, Gastrointestinal stromal tumour, Aplastic anaemia, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Moyamoya disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 6 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 3320242025: 112025

5 hospitals in Beijing for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrent / metastatic diseaseInduction / concurrent chemotherapyImmunotherapy
Departments in papersENT / head & neck surgeryPediatricsMedical oncology
Papers it led6
  1. ANKRD22 Induced by Transcription Factor MAZ Promotes Proliferation and Invasion of Nasopharyngeal Carcinoma.2025Journal of biochemical and molecular toxicology
  2. Surgical treatment and prognosis of recurrent and radiotherapy insensitive nasopharyngeal carcinoma.2024Brazilian journal of otorhinolaryngologyFree full text
  3. Case report: Immunotherapy-based combination therapy achieving complete remission and prolonged survival in nasopharyngeal carcinoma with extensive bone marrow metastasis.2024Frontiers in immunologyFree full text
  4. Surgical treatment of nasopharyngeal cancer - a consensus recommendation from two Chinese associations.2024Rhinology
  5. Effects of Arctigenin in Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma 5-8F Cells.2023Anti-cancer agents in medicinal chemistryFree full text
  6. Letter to the editor: The efficacy and safety of VEGF/VEGFR inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma.2023Oral oncology
Chinese-language papers (not in the count)1
  1. [Nasopharyngeal carcinoma in children: clinical analysis of 6 cases and literature review].2025Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatricsFree full text
More papers found outside PubMed (not counted)1
  1. WITHDRAWN: 1440TiP Phase III randomized trial of tislelizumab plus gemcitabine/capecitabine(GX) versus tislelizumab plus gemcitabine/cisplatin(GP) as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma: A prospective multic2025Annals of Oncologyretraction

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 1 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.03%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

13 hospitals in Beijing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 30 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
30
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 6620222023: 5520232024: 8820242025: 662025

17 hospitals in Beijing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyGastroenterology / hepatologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led30
  1. SLC7A11-HSPB1 axis: A novel mechanism for hepatocellular carcinoma progression and ferroptosis regulation.2026Biomedical journalFree full text
  2. SESTD1 as a potential prognostic biomarker associated with tumor aggressiveness and immune infiltration in hepatocellular carcinoma.2025Clinics (Sao Paulo, Brazil)Free full text
  3. Phthalates promote lenvatinib resistance in hepatocellular carcinoma through the HPX-MAPK pathway.2025Ecotoxicology and environmental safety
  4. The predictive value of the neutrophil/eosinophil ratio in cancer patients undergoing immune checkpoint inhibition: a meta-analysis and a validation cohort in hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  5. -A novel peptide SMIM45-107aa promotes HCC progression via MTDH pathways and its anticancer peptide derivative.2025Journal of translational medicineFree full text
  6. miRNA-338-3p influences the liver cancer stem cells and lenvatinib resistance properties by targeting SOX4.2025Scientific reportsFree full text
  7. Sorafenib with or without co-interventions for hepatocellular carcinoma.2025The Cochrane database of systematic reviewsFree full text
  8. Identification of VEGFs-related gene signature for predicting microangiogenesis and hepatocellular carcinoma prognosis.2024AgingFree full text
  9. Expression and Clinical Significance of Nuclear Phosphoglucomutase-1 in Hepatocellular Carcinoma.2024Applied immunohistochemistry & molecular morphology : AIMM
  10. Predicting Survival Using Whole-Liver MRI Radiomics in Patients with Hepatocellular Carcinoma After TACE Refractoriness.2024Cardiovascular and interventional radiology
  11. Clinical significance of ribosome production factor 2 homolog in hepatocellular carcinoma.2024Clinics and research in hepatology and gastroenterology
  12. Upregulation of miR-3130-5p Enhances Hepatocellular Carcinoma Growth by Suppressing Ferredoxin 1 : miR-3130-5p Enhances HCC Growth via Inhibiting FDX1.2024Current molecular pharmacology
  13. CD151-enriched migrasomes mediate hepatocellular carcinoma invasion by conditioning cancer cells and promoting angiogenesis.2024Journal of experimental & clinical cancer research : CRFree full text
  14. Human Umbilical Cord Mesenchymal Stem Cells-derived Exosomal lncRNA FAM99B Represses Hepatocellular Carcinoma Cell Malignancy.2024Molecular biotechnology
  15. Peptidomic analysis reveals novel peptide PDLC promotes cell proliferation in hepatocellular carcinoma via Ras/Raf/MEK/ERK pathway.2024Scientific reportsFree full text
  16. TMEM147 Correlates with Immune Infiltration and Serve as a Potential Prognostic Biomarker in Hepatocellular Carcinoma.2023Analytical cellular pathology (Amsterdam)Free full text
  17. Systematic analysis of the prognostic and immunological role of DHX33 in pan-cancer.2023Environmental toxicology
  18. Combining WGCNA and machine learning to construct basement membrane-related gene index helps to predict the prognosis and tumor microenvironment of HCC patients and verifies the carcinogenesis of key gene CTSA.2023Frontiers in immunologyFree full text
  19. Aberrant alteration of peripheral B lymphocyte subsets in hepatocellular carcinoma patients.2023International journal of medical sciencesFree full text
  20. Ubiquitin ligase MARCH8 promotes the malignant progression of hepatocellular carcinoma through PTEN ubiquitination and degradation.2023Molecular carcinogenesis
  21. Post-hepatectomy liver failure prediction and prevention: Development of a nomogram containing postoperative anticoagulants as a risk factor.2022Annals of hepatology
  22. LncRNA ST8SIA6-AS1 facilitates hepatocellular carcinoma progression by governing miR-651-5p/TM4SF4 axis.2022Anti-cancer drugs
  23. Kynurenine catabolic enzyme KMO regulates HCC growth.2022Clinical and translational medicineFree full text
  24. Cytochrome P450 3A5 polymorphism affects the metabolism of sorafenib and its toxicity for hepatocellular carcinoma cells in vitro.2022Human & experimental toxicology
  25. Circular RNA circ_0008934 promotes hepatocellular carcinoma growth and metastasis through modulating miR-1305/TMTC3 axis.2022Human cell
  26. A novel anti-lung cancer agent inhibits proliferation and epithelial-mesenchymal transition.2022The Journal of international medical researchFree full text
  27. APCCDC20-mediated degradation of PHD3 stabilizes HIF-1a and promotes tumorigenesis in hepatocellular carcinoma.2021Cancer letters
  28. Hsa_circ_0007456 regulates the natural killer cell-mediated cytotoxicity toward hepatocellular carcinoma via the miR-6852-3p/ICAM-1 axis.2021Cell death & diseaseFree full text
  29. Down-regulation of PR/SET domain 10 underlies natural killer cell dysfunction in hepatocellular carcinoma.2021Clinical and experimental immunology
  30. Kynurenine derivative 3-HAA is an agonist ligand for transcription factor YY1.2021Journal of hematology & oncologyFree full text
Chinese-language papers (not in the count)1
  1. [Morin induces autophagy and apoptosis in hepatocellular carcinoma cells through Akt/mTOR/STAT3 pathway].2023Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
All its trials on ClinicalTrials.gov, any status1
  1. A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB PatientsStatus unknownNCT05671315Study siteN/AStart 2019-07

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 15 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
15
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 6620212022: 3320222023: 4420232024: 2220242025: 002025

15 hospitals in Beijing for stomach cancer218 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & AIPeritoneal spread & advanced diseaseNutrition & recovery
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led15
  1. SUMOylation-induced membrane localization of TRPV1 suppresses proliferation and migration in gastric cancer cells.2024Cell communication and signaling : CCSFree full text
  2. Circular RNA circRNA_100349 functions as a miR-218-5p sponge for suppressing the cell proliferation of gastric cancer via regulation of IGF2 expression.2024Clinics (Sao Paulo, Brazil)Free full text
  3. LINC00115 promotes gastric cancer partly by the miR-212-5p/ATPAF1 axis.2023Anais da Academia Brasileira de Ciencias
  4. MiR-455-3p inhibits gastric cancer progression by repressing Wnt/β-catenin signaling through binding to ARMC8.2023BMC medical genomicsFree full text
  5. Construction and validation of a novel senescence-related risk score can help predict the prognosis and tumor microenvironment of gastric cancer patients and determine that STK40 can affect the ROS accumulation and proliferation ability of 2023Frontiers in immunologyFree full text
  6. Factors Influencing Postoperative Recovery Time of Patients With Gastric Cancer.2023Surgical laparoscopy, endoscopy & percutaneous techniques
  7. Zinc finger protein 852 is essential for the proliferation, drug sensitivity, and self-renewal of gastric cancer cells.2022Cell biology international
  8. MiR-4268 suppresses gastric cancer genesis through inhibiting keratin 80.2022Cell cycle (Georgetown, Tex.)Free full text
  9. m6A RNA methylation-mediated NDUFA4 promotes cell proliferation and metabolism in gastric cancer.2022Cell death & diseaseFree full text
  10. Tumor Exosomes Reprogrammed by Low pH Are Efficient Targeting Vehicles for Smart Drug Delivery and Personalized Therapy against their Homologous Tumor.2021Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  11. MiR-643 Functions as a Potential Tumor Suppressor in Gastric Cancer by Inhibiting Cell Proliferation and Invasion via Targeting TXNDC9.2021Annals of clinical and laboratory science
  12. The Immune Subtypes and Landscape of Gastric Cancer and to Predict Based on the Whole-Slide Images Using Deep Learning.2021Frontiers in immunologyFree full text
  13. FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway.2021Molecular oncologyFree full text
  14. lncRNA SNHG11 Promotes Gastric Cancer Progression by Activating the Wnt/β-Catenin Pathway and Oncogenic Autophagy.2021Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  15. LINC00665 promotes cell proliferation, invasion, and metastasis by activating the TGF-β pathway in gastric cancer.2021Pathology, research and practice
All its trials on ClinicalTrials.gov, any status1
  1. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 8 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 5.2%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 1120222023: 1120232024: 1120242025: 002025

9 hospitals in Beijing for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led8
  1. Individualized chemotherapy and efficacy analysis of hepatoblastoma in children.2024Pediatric blood & cancer
  2. Lung and right atrial metastases from hepatoblastoma in children: A case series and literature review.2023Indian journal of cancer
  3. Clinical application of irinotecan combined with first-line chemotherapeutics against pediatric hepatoblastoma with pulmonary metastasis.2022Pakistan journal of pharmaceutical sciences
  4. Prognostic analysis for children with hepatoblastoma with lung metastasis: A single-center analysis of 98 cases.2021Asia-Pacific journal of clinical oncology
  5. A new risk-stratification system for hepatoblastoma in children under six years old and the significance for prognosis evaluation-a 14-year retrospective study from a single center.2021BMC cancer
  6. Clinical characteristics and prognostic factors of hepatoblastoma in 316 children aged under 3 years - a 14-year retrospective single-center study.2021BMC pediatrics
  7. Prevalence, clinical features and prognosis of malignant solid tumors in infants: a 14-year study.2021Bosnian journal of basic medical sciences
  8. Factors influencing recurrence after complete remission in children with hepatoblastoma: A 14-year retrospective study in China.2021PloS one
Chinese-language papers (not in the count)2
  1. [Establishment of a patient-derived xenograft humanized mouse model for hepatoblastoma in children].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  2. [Clinical features and prognostic analysis of hepatoblastoma in children under six years old].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
Earlier papers (2016–2020)1
  1. Short-term prognosis of childhood hepatoblastoma in relation to ERCC1 C118T single nucleotide polymorphism and VEGF expression.2019Polish journal of pathology : official journal of the Polish Society of Pathologists

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 21 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 7.0%.

Papers led
21
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 6620212022: 1120222023: 7720232024: 5520242025: 222025

10 hospitals in Beijing for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmologyPediatricsRadiology / nuclear medicine
Papers it led21
  1. Long-Term Observation of Orbital Development in Patients With Retinoblastoma Following Unilateral Enucleation.2025Cancer medicine
  2. GD2-CAR-Engineered Microglia Exhibit Antitumor Effects in Organoids and Animal Models of Retinoblastoma.2025Investigative ophthalmology & visual science
  3. Enhancement of vincristine sensitivity in retinoblastoma through Janus kinase inhibition by ruxolitinib.2024Anti-cancer drugs
  4. Characteristics of patients with recurrent retinoblastoma: a survival analysis.2024BMC cancer
  5. Clinical characterization and long-term postoperative outcomes of retinoblastoma patients receiving enucleation and primary orbital implantation in early infancy: an observational study.2024BMC ophthalmology
  6. Progress of Cancer Stem Cells in Retinoblastoma.2024Current stem cell research & therapy
  7. Enhanced innate responses in microglia derived from retinoblastoma patient-specific iPSCs.2024Glia
  8. Incidental detection of retinoblastoma from accidental trauma in children.2023BMC ophthalmology
  9. Clinical characteristics, treatment and prognosis of infants with retinoblastoma: a multicenter, 10-year retrospective analysis.2023BMC pediatrics
  10. Automatic retinoblastoma screening and surveillance using deep learning.2023British journal of cancer
  11. MRI features for prediction of the intravenous chemotherapy effect in patients with retinoblastoma.2023Clinical radiology
  12. Value of the strain ratio in the differential diagnosis of intraocular tumors by elastosonography: A retrospective case-control study.2023Indian journal of ophthalmology
  13. Diffusion-Weighted MR Imaging of the Optic Nerve Can Improve the Detection of Post-Laminar Optic Nerve Invasion from Retinoblastoma.2023Journal of magnetic resonance imaging : JMRI
  14. Clinical analysis of 2790 children with retinoblastoma: a single-center experience in China.2023World journal of pediatrics : WJP
  15. MRI-based radiomics model can improve the predictive performance of postlaminar optic nerve invasion in retinoblastoma.2022The British journal of radiology
  16. Clinical characteristics, treatment and prognosis of children with unilateral retinoblastoma and intracranial segment of Retrobulbar optic nerve invasion.2021BMC ophthalmology
  17. Prevalence, clinical features and prognosis of malignant solid tumors in infants: a 14-year study.2021Bosnian journal of basic medical sciences
  18. Case report: Delayed retinoblastoma relapse in a lymph node after 9 years of complete remission.2021Current problems in cancer
  19. Correlation between Family RB1 Gene Pathogenic Variant with Clinical Features and Prognosis of Retinoblastoma under 5 Years Old.2021Disease markers
  20. Clinical features and imaging manifestations of retinoblastoma with hepatic metastasis.2021Pediatric blood & cancer
  21. Modeling human retinoblastoma using embryonic stem cell-derived retinal organoids.2021STAR protocols
Chinese-language papers (not in the count)2
  1. [Reflection on the origin and pathogenesis of retinoblastoma].2024[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  2. [A case of diffuse anterior retinoblastoma].2022[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
Earlier papers (2016–2020)15
  1. RRS1 Promotes Retinoblastoma Cell Proliferation and Invasion via Activating the AKT/mTOR Signaling Pathway.2020BioMed research international
  2. KLF16 overexpression deleteriously affects the proliferation and migration of retinoblastoma by transcriptionally repressing BCL2L15.2020Biochemical and biophysical research communications
  3. Diagnosis of Postlaminar Optic Nerve Invasion in Retinoblastoma With MRI Features.2020Journal of magnetic resonance imaging : JMRI
  4. Human embryonic stem cell-derived organoid retinoblastoma reveals a cancerous origin.2020Proceedings of the National Academy of Sciences of the United States of America
  5. Effects of lentivirus-mediated astrocyte elevated gene-1 overexpression on proliferation and apoptosis of human retinoblastoma cells.2019Acta ophthalmologica
  6. Long non-coding RNAs in retinoblastoma.2019Pathology, research and practice
  7. [Analysis of the histopathological features of recurrent retinoblastoma after vitrectomy].2019[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  8. Characterization, treatment and prognosis of retinoblastoma with central nervous system metastasis.2018BMC ophthalmology
  9. [Analysis of high-risk histopathologic features of 482 primarily enucleated retinoblastomas].2018[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  10. [Cautious choice of vitrectomy in patients with retinoblastoma].2018[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  11. [Clinical features, treatment and prognosis of retinoblastoma in distant metastasis stage].2017[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  12. Scleral and choroidal volume in relation to axial length in infants with retinoblastoma versus adults with malignant melanomas or end-stage glaucoma.2016Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  13. Lentivirus-Mediated Knockdown of Astrocyte Elevated Gene-1 Inhibits Growth and Induces Apoptosis through MAPK Pathways in Human Retinoblastoma Cells.2016PloS one
  14. SCLERAL AND CHOROIDAL THICKNESS IN SECONDARY HIGH AXIAL MYOPIA.2016Retina (Philadelphia, Pa.)
  15. [Treatment and prognostic analysis of retinoblastoma patients with choroid invasion].2016Zhonghua er ke za zhi = Chinese journal of pediatrics
All its trials on ClinicalTrials.gov, any status1
  1. Deep Learning in Retinoblastoma Detection and Monitoring.Status unknownNCT05308043Lead sponsorStart 2020-03

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 7 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 3320222023: 0020232024: 0020242025: 112025

48 hospitals in Beijing for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineMedical oncologyPediatrics

Over half of these papers are lab or animal studies.

Papers it led7
  1. Ailanthone targets the KMT2A-MEN1 complex to suppress lung metastasis of osteosarcoma.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  2. MiR-140 targets Wnt1 to inhibit the proliferation and enhance drug sensitivity in osteosarcoma cells.2022Cellular and molecular biology (Noisy-le-Grand, France)
  3. Automated prediction of the neoadjuvant chemotherapy response in osteosarcoma with deep learning and an MRI-based radiomics nomogram.2022European radiology
  4. IRF7 inhibits the Warburg effect via transcriptional suppression of PKM2 in osteosarcoma.2022International journal of biological sciences
  5. Prevalence, clinical features and prognosis of malignant solid tumors in infants: a 14-year study.2021Bosnian journal of basic medical sciences
  6. A systematic review of radiomics in osteosarcoma: utilizing radiomics quality score as a tool promoting clinical translation.2021European radiology
  7. Clinicopathologic significance and prognostic value of circRNAs in osteosarcoma: a systematic review and meta-analysis.2021Journal of orthopaedic surgery and research
Earlier papers (2016–2020)9
  1. Chondromyxoid fibroma-like osteosarcoma: a case series and literature review.2020BMC musculoskeletal disorders
  2. Targeting USP9x/SOX2 axis contributes to the anti-osteosarcoma effect of neogambogic acid.2020Cancer letters
  3. LncRNA TTN-AS1 regulates osteosarcoma cell apoptosis and drug resistance via the miR-134-5p/MBTD1 axis.2019Aging
  4. Inhibition of mitochondrial translation selectively targets osteosarcoma.2019Biochemical and biophysical research communications
  5. miR-186-5p Functions as a Tumor Suppressor in Human Osteosarcoma by Targeting FOXK1.2019Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  6. miR-181d-5p-FOXP1 feedback loop modulates the progression of osteosarcoma.2018Biochemical and biophysical research communications
  7. Knockdown of HuR represses osteosarcoma cells migration, invasion and stemness through inhibition of YAP activation and increases susceptibility to chemotherapeutic agents.2018Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  8. LncRNA B4GALT1-AS1 recruits HuR to promote osteosarcoma cells stemness and migration via enhancing YAP transcriptional activity.2018Cell proliferation
  9. RNA-binding protein PUM2 suppresses osteosarcoma progression via partly and competitively binding to STARD13 3'UTR with miRNAs.2018Cell proliferation

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 9 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 3320232024: 2220242025: 002025

24 hospitals in Beijing for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsPathology / laboratory medicineENT / head & neck surgeryRadiology / nuclear medicine
Papers it led9
  1. The syndrome of inappropriate antidiuretic hormone associated with nasal and paranasal malignant tumors.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  2. The role of insulinoma-associated protein 1 in predicting the progression and prognosis of human olfactory neuroblastoma in China.2024Pathology, research and practice
  3. Prognostic factors for intermediate- or high-risk neuroblastomas in children in China.2023BMC pediatrics
  4. Correlation between ARID1B gene mutation (p.A460, p.V215G) and prognosis of high-risk refractory neuroblastoma.2023Cell biology international
  5. LINC00938 alleviates hypoxia ischemia encephalopathy induced neonatal brain injury by regulating oxidative stress and inhibiting JNK/p38 MAPK signaling pathway.2023Experimental neurology
  6. The role of ADC value and Ki-67 index in predicting the response to neoadjuvant chemotherapy in advanced stages of olfactory neuroblastoma.2022The British journal of radiology
  7. Clinicopathologic Features and Prognosis of Olfactory Neuroblastoma with Isocitrate Dehydrogenase 2 Mutations.2022World neurosurgery
  8. Prevalence, clinical features and prognosis of malignant solid tumors in infants: a 14-year study.2021Bosnian journal of basic medical sciences
  9. Outcomes and Quality-of-Life Measures after Endoscopic Endonasal Resection of Kadish Stage C Olfactory Neuroblastomas.2021World neurosurgery
Chinese-language papers (not in the count)3
  1. [Genomic profiles and immune microenvironment of olfactory neuroblastoma].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Olfactory neuroblastoma in children: clinical analysis of five cases].2024Zhonghua yi xue za zhi
  3. [Neoadjuvant chemotherapy in the treatment of locally advanced olfactory neuroblastoma in 25 cases].2023Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
Earlier papers (2016–2020)3
  1. MicroRNA-145 suppresses uveal melanoma angiogenesis and growth by targeting neuroblastoma RAS viral oncogene homolog and vascular endothelial growth factor.2020Chinese medical journal
  2. Clinical characteristics, treatment and prognosis of paediatric patients with metastatic neuroblastoma to the brain.2019Clinical neurology and neurosurgery
  3. [Clinical features and outcomes of neuroblastoma patients aged above 5 years].2016Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

17 hospitals in Beijing for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 6 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.4%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 2220242025: 112025

15 hospitals in Beijing for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDrug combinationsCAR-T & cell therapyBispecific & antibody drugs

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution

10 hospitals in Beijing for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT06081478

    Age 14 years to 85 years (registered criteria)

    Led by Beijing Tongren HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic LeukemiaRecruitingNCT06081478Lead sponsorPhase 2Start 2022-01

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 1 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

11 hospitals in Beijing for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Registry
    NCT07525466

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tongren HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesTreatment regimensLymphoma & cancer-related HLHDiagnosis & prognosis

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

15 hospitals in Beijing for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [A case of pseudotumor of lower extremity combined with protracted infectious skin ulcer induced by severe hemophilia A].2021Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns
All its trials on ClinicalTrials.gov, any status1
  1. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 7 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 1.4%.

Papers led
7
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 1120242025: 332025

12 hospitals in Beijing for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesOptic nerve & visionAntibodies & diagnosisPregnancy, children, older adults
Departments in papersNeurologyRadiology / nuclear medicineOphthalmology / neuro-ophthalmologyClinical trials / research unit
Papers it led7
  1. Abnormal dynamic features of spontaneous brain activity and their concordance in neuromyelitis optica spectrum disorder related optic neuritis: A resting-state fMRI study.2025Brain research
  2. Genetic Insights into Therapeutic Targets for Neuromyelitis Optica Spectrum Disorders: A Mendelian Randomization Study.2025Molecular neurobiology
  3. Acetylcarnitine in cerebrospinal fluid and blood as a protective factor for neuromyelitis optica spectrum disorders: a mendelian randomization study.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  4. Clinical features and visual prognosis of very late-onset neuromyelitis optica spectrum disorder-related optic neuritis.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  5. The imbalance between Bregs, Tfh, and Tregs in patients with anti-N-methyl-D-aspartate receptor encephalitis.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyFree full text
  6. ABCB1 gene polymorphisms impact the effect of high-dose intravenous methylprednisolone therapy on optic neuritis associated with AQP4-IgG-positive neuromyelitis optica spectrum disorder.2022Journal of clinical pharmacy and therapeutics
  7. Factors influencing intravenous methylprednisolone pulse therapy in Chinese patients with isolated optic neuritis associated with AQP4 antibody-seropositive neuromyelitis optica.2021Scientific reportsFree full text
Chinese-language papers (not in the count)1
  1. [The analysis of features of first-onset neuromyelitis optica spectrum disease within 1 year after delivery].2023Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
All its trials on ClinicalTrials.gov, any status3
  1. Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica (NMO) and Gene PolymorphismStatus unknownNCT04601142Lead sponsorStart 2020-10
  2. Clinic Registry Study of Optic Neuromyelitis Spectrum Disease in ChinaStatus unknownNCT03514030Lead sponsorStart 2018-04
  3. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 3 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 1.2%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

11 hospitals in Beijing for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesHead, eye socket & salivary glandsDiagnosis & look-alikes
Departments in papersPathology / laboratory medicineOphthalmology / neuro-ophthalmologyRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 6 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 1.2%.

Papers led
6
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 332025

11 hospitals in Beijing for myasthenia gravis93 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesThymus & thymectomy
Departments in papersNeurologyOphthalmology / neuro-ophthalmologyClinical trials / research unitPathology / laboratory medicine
Papers it led6
  1. Sugammadex versus Neostigmine Reversal After Thoracoscopic Thymectomy in Myasthenia Gravis: A Multicenter, Randomized Controlled Trial.2025Drug design, development and therapyRCTFree full text
  2. Identification and characteristics of a novel CD8αα T cell subset in a refractory myasthenia gravis patient.2025Journal of neuroimmunology
  3. Gut microbial profiles of patients with optic neuritis or myasthenia gravis.2025The Journal of international medical researchFree full text
  4. The rate of QMGS change predicts recurrence after thymectomy in myasthenia gravis.2024Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  5. Vitamin D receptor gene polymorphisms are associated with the risk and features of myasthenia gravis in the Han Chinese population.2023Immunologic research
  6. LncRNA and mRNA expression associated with myasthenia gravis in patients with thymoma.2022Thoracic cancerFree full text
Chinese-language papers (not in the count)2
  1. [Research progress on the manifestations prevention and treatment of immune-related adverse events in the neuro-ophthalmic efferent system related to immune checkpoint inhibitors].2025[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  2. [Factors related to myasthenic crisis in myasthenia gravis patients with oropharyngeal involvement during hospitalization].2021Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status4
  1. Efficacy and Safety of Sugammadex in Thoracoscopy Thymectomy for Chinese Adults With Myasthenia GravisCompletedNCT06436768Lead sponsorN/AStart 2024-06
  2. Association Study Between VDR Gene Polymorphisms and Risk and Features of MG in Han Chinese PopulationCompletedNCT05380128Lead sponsorStart 2017-06
  3. A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia GravisTerminatedNCT04963270Study sitePhase 3Start 2021-10
  4. A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia GravisCompletedNCT04302103Study sitePhase 2Start 2020-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Wilson disease

肝豆状核变性(Wilson 病)

Led 3 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 1.5%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 002025

3 hospitals in Beijing for Wilson disease28 hospitals in China for Wilson disease

No open trial on Wilson disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesGenetics (ATP7B)Diagnosis & copper testsLiver disease & transplant
Departments in papersNeurologyOphthalmology / neuro-ophthalmologyRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 4 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 1.5%.

Papers led
4
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 112025

13 hospitals in Beijing for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efgartigimod in Anti-NMDA Receptor Encephalitis.
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07822776

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tongren HospitalBeijing

  2. Recruiting
    Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06510283

    Age 14 years to Not stated (registered criteria)

    Led by Beijing Tongren HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurology
Papers it led4
  1. Exosomal miR-432-5p, miR-4433b-5p, and miR-599: Biomarkers for Monitoring the Severity of Anti-N-methyl-D-aspartate Receptor Encephalitis.2025Journal of integrative neuroscience
  2. Development of a short-term prognostic model for anti-N-methyl-D-aspartate receptor encephalitis in Chinese patients.2024BMC neurology
  3. Factors influencing prognosis and relapse in patients with anti-N-methyl-D-aspartate receptor encephalitis.2023Multiple sclerosis and related disorders
  4. The imbalance between Bregs, Tfh, and Tregs in patients with anti-N-methyl-D-aspartate receptor encephalitis.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyFree full text
Chinese-language papers (not in the count)1
  1. [Analysis of the risk factors for poor prognosis and recurrence in patients with anti-NMDAR encephalitis].2023Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
Earlier papers (2016–2020)2
  1. Validation of the NEOS score in Chinese patients with anti-NMDAR encephalitis.2020Neurology(R) neuroimmunology & neuroinflammation
  2. Application of the 2016 diagnostic approach for autoimmune encephalitis from Lancet Neurology to Chinese patients.2017BMC neurology
All its trials on ClinicalTrials.gov, any status4
  1. Efgartigimod in Anti-NMDA Receptor Encephalitis.RecruitingNCT07822776Lead sponsorPhase 2Start 2026-06
  2. Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 EncephalitisRecruitingNCT06510283Lead sponsorPhase 2Start 2024-12
  3. Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in Beijing AreaStatus unknownNCT02443350Lead (inferred)Start 2014-06
  4. A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisActive, not recruitingNCT05503264Study sitePhase 3Start 2022-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

27 hospitals in Beijing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

24 hospitals in Beijing for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgery
Papers it led1
  1. Surgical Intervention to Treat Pharyngolaryngeal Stenosis Caused by Behcet's Disease.2024Ear, nose, & throat journal
Earlier papers (2016–2020)2
  1. Primary optic neuropathy in Behçet's syndrome.2019Multiple sclerosis (Houndmills, Basingstoke, England)
  2. [The value of different antibodies detection in diagnosis of rheumatism with uveitis].2017Zhonghua yi xue za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

32 hospitals in Beijing for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 2 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

16 hospitals in Beijing for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunologyGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 1 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

8 hospitals in Beijing for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology
Papers it led1
  1. Waardenburg syndrome type 4 coexisting with open-angle glaucoma: a case report.2022Journal of medical case reports
Earlier papers (2016–2020)1
  1. Identification of a de novo mutation of SOX10 in a Chinese patient with Waardenburg syndrome type IV.2016International journal of pediatric otorhinolaryngology

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led no English-language PubMed papers on hereditary angioedema in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Beijing for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Two cases of laryngeal obstruction with hereditary angioedema].2019Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 4 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 7.7%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 222025

3 hospitals in Beijing for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy
    Phase
    Phase 2/Phase 3
    Started
    2021-06
    Registry
    NCT04912843

    Age 12 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmologyNeurology
Papers it led4
  1. Efficacy and safety of intravitreal rAAV2-ND4 therapy for Leber's hereditary optic neuropathy.2025Eye (London, England)
  2. Quantitative assessment of retinal microvasculature using optical coherence tomography angiography and correlation with visual acuity in leber's hereditary optic neuropathy.2025International ophthalmology
  3. Optic nerve lesion length is a biomarker of visual disability in the pre-chronic phase of Leber's hereditary optic neuropathy.2023Clinical neurology and neurosurgery
  4. Magnetic Resonance Imaging Findings in the Pregeniculate Visual Pathway in Leber Hereditary Optic Neuropathy.2022Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
Chinese-language papers (not in the count)2
  1. [Evaluation of retinal microvascular characteristics in Leber hereditary optic neuropathy based on optical coherence tomography angiography].2025Zhonghua yi xue za zhi
  2. [Clinical characteristics and research progress on the treatment of mitochondrial optic neuropathy].2021[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
Earlier papers (2016–2020)3
  1. Clinical Features of Chinese Sporadic Leber Hereditary Optic Neuropathy Caused by Rare Primary mtDNA Mutations.2020Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  2. Bioenergetic Crosstalk between Mesenchymal Stem Cells and various Ocular Cells through the intercellular trafficking of Mitochondria.2020Theranostics
  3. Evaluation of Vision-Related Quality of Life in Chinese Patients With Leber Hereditary Optic Neuropathy and the G11778A Mutation.2019Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
All its trials on ClinicalTrials.gov, any status2
  1. Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic NeuropathyRecruitingNCT04912843Study sitePhase 2/Phase 3Start 2021-06
  2. A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 MutationActive, not recruitingNCT07406854Study sitePhase 3Start 2024-09

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

首都医科大学附属北京同仁医院

Beijing Tongren Hospital

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Tongren Hospital; Shanghai Tongren Hospital; Beijing Tongren Eye Center; Beijing TongRen Hospital; Wuhan Third Hospital (Tongren Hospital of Wuhan University); Tongren Hospital of Wuhan University (Wuhan Third Hospital); Tongren Hospital of Wuhan University; Shanghai Tongren Hospital/Faculty of Basic Medicine

Suggest a correctionDownload the data